SCHEDULE: Matrix Capital Exits Zentalis Pharmaceuticals Stake

Matrix Capital Management and David E. Goel have completed an exit filing, reporting zero beneficial ownership in Zentalis Pharmaceuticals after a private sale of shares.

Summary

• Matrix Capital Management Company, LP and David E. Goel filed Amendment No. 3 to their Schedule 13D, which serves as an "exit filing" for the reporting persons.
• The reporting persons no longer beneficially own any shares of Zentalis Pharmaceuticals, Inc. Common Stock.
• This change resulted from a private sale of 6,459,973 shares of Common Stock by the Matrix Fund to an accredited investor.
• The shares were sold at a price of $1.20 per share.
• The private sale closed on December 31, 2025, with the agreement for the sale occurring on December 30, 2025.

Sentiment

Score: 5

Explanation: Neutral. The filing is a factual report of an investor's complete divestment, which is neither inherently positive nor negative for the company itself without further context. It simply marks the end of a significant shareholder's position.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investor, Matrix Capital Management, has fully divested its stake in Zentalis Pharmaceuticals. Such divestments by major funds can sometimes signal a change in investment thesis or a re-evaluation of the company's prospects, potentially influencing other investors' perceptions, especially in the biotechnology or pharmaceutical sector where investor confidence is crucial.

Stakeholder Impact

• Shareholders: The divestment by a significant institutional investor could lead to increased scrutiny or a re-evaluation of Zentalis Pharmaceuticals, Inc. by other investors, potentially impacting share price volatility.

Key Dates

Keywords

Zentalis Pharmaceuticals, Matrix Capital Management, David E. Goel, Schedule 13D, exit filing, beneficial ownership, private sale, common stock, institutional investor